Evommune, Inc.

EVMN

NYSE; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0002044725

None

No letter

2 of 13 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $224.9M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	thin data not computable: dilution, distress, fortress balance sheet
Inputs computable	2 of 13
Graded from	filings received through Mar 5, 2026 258 days before the rescan; latest periodic filing 10-Q received Nov 12, 2026
Last close	$7.03 2026-11-17; market equity $290.5M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 5, 2026

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria ("CSU"), atopic dermatitis ("AD") and ulcerative colitis ("UC"). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients' quality of life and leading to life-threatening conditions.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability						
Gross profitability	not computable	32.8%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.6%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	not computable	(6.7%)				
a prior annual assets observation is required						
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 15.4						
Altman Z double-prime	9.47	0.31		9.8	705	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(3.61x)				
one or more required annual facts are missing						
Current ratio	8.57x	2.68x		21.0	781	2025-12-31
Growth and financing						
Revenue growth, three-year compound	not computable	9.6%				
four annual observations are required; found 1						
Free cash flow growth, three-year compound	not computable	11.1%				
four consecutive annual FCF observations are required; found 1						
Reinvestment rate	not computable	33.9%				
a prior annual working-capital observation is required						
Asset growth, three years	not computable	3.2%				
four annual observations are required; found 1						
Net share issuance, one year	not computable	1.6%				
two annual share counts are required; found 1						

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	2 of 13 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-17 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	not computable	(1.7%)	
Distance from 52-week high	(77.8%)	(30.5%)	10
EBIT to enterprise value	not computable	0.5%	
Free cash flow yield	(26.4%)	0.5%	18
Book value to price	0.87	0.28	82
Sales to price	0.04	0.36	10
Composite equity issuance, five years	not computable	13.5%	
Relative strength against the sector, log excess return	not computable	(0.19)	
Twelve-month failure probability, CHS model	not computable	0.06%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$47.6M
Operating cash flow, four quarters	-$90.4M
Months of runway	6.3
Days since last periodic filing	6 (10-Q received Nov 12, 2026)
Median daily dollar volume, 63 sessions	$5.1M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$68.9M	2025-12-31	2026-03-05	10-K	26-093932
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$76.4M	2025-12-31	2026-03-05	10-K	26-093932
3	assets	us-gaap:Assets	$224.9M	2025-12-31	2026-03-05	10-K	26-093932
4	current assets	us-gaap:AssetsCurrent	$153.5M	2025-12-31	2026-03-05	10-K	26-093932
5	current liabilities	us-gaap:LiabilitiesCurrent	$17.9M	2025-12-31	2026-03-05	10-K	26-093932
6	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$221.1M	2025-12-31	2026-03-05	10-K	26-093932
7	operating income	us-gaap:OperatingIncomeLoss	-$81.1M	2025-12-31	2026-03-05	10-K	26-093932
8	book equity	us-gaap:StockholdersEquity	$205.6M	2025-12-31	2026-03-05	10-K	26-093932
9	liabilities	us-gaap:Liabilities	$19.4M	2025-12-31	2026-03-05	10-K	26-093932
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$13.0M	2025-12-31	2026-03-05	10-K	26-093932
11	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$235,000	2025-12-31	2026-03-05	10-K	26-093932
12	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$600,000	2025-12-31	2026-03-05	10-K	26-093932
13	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$68.9M	2025-12-31	2026-03-05	10-K	26-093932
14	income tax	us-gaap:IncomeTaxExpenseBenefit	$0	2025-12-31	2026-03-05	10-K	26-093932
15	shares outstanding	dei:EntityCommonStockSharesOutstanding	36,018,372	2026-03-03	2026-03-05	10-K	26-093932

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.